Extensive molecular and clinical heterogeneity in patients with histologically diagnosed cns-pnet treated as a single entity: a report from the children’s oncology group randomized ACNS0332 trial
Children with histologically diagnosed high-risk medulloblastoma, supratentorial primitive neuroectodermal tumor of the CNS (CNS-PNET), and pineoblastoma (PBL) have had poor survival despite intensive treatment. We included these patients in this Children’s Oncology Group trial. Molecular profiling...
Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
December 1, 2018
|
| In: |
Journal of clinical oncology
Year: 2018, Volume: 36, Issue: 34, Pages: 3388-3395 |
| ISSN: | 1527-7755 |
| DOI: | 10.1200/JCO.2017.76.4720 |
| Online Access: | Resolving-System, Volltext: http://dx.doi.org/10.1200/JCO.2017.76.4720 Verlag, Volltext: http://ascopubs.org/doi/10.1200/JCO.2017.76.4720 
|
| Author Notes: | Eugene I. Hwang, Marcel Kool, Peter C. Burger, David Capper, Lukas Chavez, Sebastian Brabetz, Chris Williams-Hughes, Catherine Billups, Linda Heier, Alok Jaju, Jeff Michalski, Yimei Li, Sarah Leary, Tianni Zhou, Andreas von Deimling, David T.W. Jones, Maryam Fouladi, Ian F. Pollack, Amar Gajjar, Roger J. Packer, Stefan M. Pfister, and James M. Olson |
| Summary: | Children with histologically diagnosed high-risk medulloblastoma, supratentorial primitive neuroectodermal tumor of the CNS (CNS-PNET), and pineoblastoma (PBL) have had poor survival despite intensive treatment. We included these patients in this Children’s Oncology Group trial. Molecular profiling later revealed tumor heterogeneity that was not detectable at protocol inception. Enrollment of patients with CNS-PNET/PBL was subsequently discontinued, and outcomes for this part of the study are reported here. |
|---|---|
| Item Description: | Gesehen am 27.11.2018 |
| Physical Description: | Online Resource |
| ISSN: | 1527-7755 |
| DOI: | 10.1200/JCO.2017.76.4720 |